Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Share Post:

Strengthen Your Customer Connections

Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today. 

Begin learning today

Achieve Company Goals

Bring teams up-to-speed on the latest market access trends impacting their unique selling environment.

View custom training solutions

Keep Your Finger on The Pulse

Subscribe to the Marketplace Blog to stay up-to-date on the latest trends impacting pharma

*required





    Privacy Guaranteed — We will never share your info

    Marketplace Blog

    Trends in the Marketplace

    Fractures in The 340B Program

    The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps

    The Impact of Medicare Price Negotiations

    The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact.

    Module Samples

    ProFusion’s portfolio of training products cover both foundational and advanced market access training topics. Foundational modules describe the structure of the market access landscape. Advanced modules reveal the competing pressures being felt by prescribers in today’s marketplace, and how clinical decisions may change as a result.

    ProFusion can provide you with any level of training, from individual module licensing to evidence-based account management with the Value Perspective Module. Contact us for more information.

    [portfolio_posts orderby=date cat=books]

    Manufacturers Restricting 340B Sales to Contract Pharmacies

    • Abbvie
    • Amgen
    • AstraZeneca
    • Boehringer Ingelheim
    • Eli Lilly
    • Merck
    • Novartis
    • Novo Nordisk
    • Sanofi
    • UCB
    • United Therapeutics
    • and more…